Related Experiment Videos
Clinical trials update in human immunodeficiency virus wasting
1Department of Medicine, Graduate Hospital and Philadelphia Field Initiating Group for HIV Trials, PA, USA.
Seminars in Oncology
|June 13, 1998
Summary
Major clinical trials groups are researching weight loss and wasting in individuals with human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS). Studies will evaluate various treatments to combat HIV-related malnutrition and wasting.
Area of Science:
- Immunology
- Infectious Diseases
- Clinical Trials
Background:
- Weight loss and wasting are significant issues for individuals with human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS).
- Major clinical trials groups, including the AIDS Clinical Trials Group (ACTG) and the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), are actively researching this condition.
Purpose of the Study:
- To review multicenter trials investigating the pathogenesis, diagnosis, prevention, and treatment of HIV-related malnutrition and wasting.
- To summarize ongoing and planned research by ACTG and CPCRA to address weight loss in HIV/AIDS patients.
Main Methods:
- CPCRA trials will assess caloric supplements, triglycerides, megestrol acetate, oxandrolone, and progressive resistance training for HIV-associated wasting.
- ACTG trials will investigate the effects of megestrol acetate/testosterone combinations, nandrolone decanoate, and highly active antiretroviral therapy on weight loss.
Main Results:
- This article reviews planned and ongoing trials, with results to be determined.
- The findings may also inform oncologists treating cancer-related cachexia.
Conclusions:
- Clinical trials groups are conducting extensive research into effective interventions for HIV-related malnutrition and wasting.
- The outcomes of these trials are anticipated to provide valuable insights for managing weight loss in HIV/AIDS patients and potentially in cancer cachexia.